Form 4: Denali Therapeutics CEO Ryan J. Watts Donates 40,000 Shares to Charity
SEC Form 4 Filing
Denali Therapeutics' CEO, Ryan J. Watts, made an in-kind charitable contribution of 40,000 shares of DNLI stock to a donor-advised fund on March 29, 2024.
Summary
- On March 29, 2024, Ryan J. Watts, the President and CEO of Denali Therapeutics Inc. (DNLI), donated 40,000 shares of DNLI common stock to a donor-advised fund.
- The transaction was an in-kind charitable contribution.
- Following the transaction, Watts directly owns 238,067 shares of common stock, including 202,200 unvested RSUs.
- He also indirectly owns 2,202,604 shares through the Watts Family 2015 Trust, for which he serves as trustee.
Sentiment
Score: 6
Explanation: The document primarily reports a charitable donation, which is generally neutral to slightly positive. There's no indication of negative sentiment, but also no strong positive drivers.
Positives
- The charitable donation may be viewed positively by stakeholders.
Industry Context
Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. Charitable donations are not typically interpreted as a negative signal.
Stakeholder Impact
- Shareholders may view the charitable donation positively.
- The donation has no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| July 7, 2015 | Date of the Watts Family 2015 Trust |
| 03/29/2024 | Date of the charitable contribution of 40,000 shares of DNLI stock |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.